MED-RIVASTIGMINE CAPSULE

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE)

Pieejams no:

GENERIC MEDICAL PARTNERS INC

ATĶ kods:

N06DA03

SNN (starptautisko nepatentēto nosaukumu):

RIVASTIGMINE

Deva:

1.5MG

Zāļu forma:

CAPSULE

Kompozīcija:

RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 1.5MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

56

Receptes veids:

Prescription

Ārstniecības joma:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0140521001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2013-02-22

Produkta apraksts

MED-RIVASTIGMINE (Rivastigmine hydrogen tartrate)
_Page 1 of 61_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
MED-RIVASTIGMINE
Rivastigmine Capsules
Capsules, 1.5 mg, 3 mg, 4.5 mg, 6 mg Rivastigmine (as rivastigmine
hydrogen tartrate), oral
Generic Medical Partners Standard
Cholinesterase Inhibitor
Generic Medical Partners Inc.
1500 Don Mills Road, Suite 711
Toronto, Ontario
M3B 3K4
Date of Initial Authorization:
February 22, 2013
Date of Revision:
MAR 05, 2024
Submission Control Number: 281869
MED-RIVASTIGMINE (Rivastigmine hydrogen tartrate)
_Page 2 of 61_
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
03/2024
7 WARNINGS AND PRECAUTIONS, Cardiovascular
03/2024
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...................................................................................................
2
TABLE OF CONTENTS
......................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................................
4
1
INDICATIONS
......................................................................................................................
4
1.1
Pediatrics
.................................................................................................................................
4
1.2
Geriatrics
.................................................................................................................................
4
2
CONTRAINDICATIONS
.........................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.........................................................................................
5
4.1
DOSING CONSIDERATIONS
........................................................................................................
5
4.2
RECOMMENDED DOSE AND DOSAGE ADJUSTMENT
........